Scientists have successfully developed a stem cell-based treatment to restore vision in patients with severe corneal injuries using their own eye stem cells.
This technique, tested in a U.S. clinical trial called CALEC, involves harvesting limbal stem cells from a patient’s healthy eye, growing them in a lab, and transplanting them into the damaged eye.
Key Results:
- 93% success rate in restoring the corneal surface.
- 72% of patients showed significant vision improvement within 12–18 months.
- No major side effects or rejection risks were observed since the treatment uses the patient’s own cells.
Why It Matters:
This breakthrough offers hope to patients with limbal stem cell deficiency, often caused by burns, trauma, or infections, where standard corneal transplants fail. Unlike traditional grafts, this approach doesn’t require donor tissue or immunosuppressive drugs and helps regenerate the cornea naturally.
Final Thought:
This is a major step forward in regenerative eye medicine, proving that personalized stem cell therapy can safely and effectively restore both the eye’s surface and vision.
This technique, tested in a U.S. clinical trial called CALEC, involves harvesting limbal stem cells from a patient’s healthy eye, growing them in a lab, and transplanting them into the damaged eye.
Key Results:
- 93% success rate in restoring the corneal surface.
- 72% of patients showed significant vision improvement within 12–18 months.
- No major side effects or rejection risks were observed since the treatment uses the patient’s own cells.
Why It Matters:
This breakthrough offers hope to patients with limbal stem cell deficiency, often caused by burns, trauma, or infections, where standard corneal transplants fail. Unlike traditional grafts, this approach doesn’t require donor tissue or immunosuppressive drugs and helps regenerate the cornea naturally.
Final Thought:
This is a major step forward in regenerative eye medicine, proving that personalized stem cell therapy can safely and effectively restore both the eye’s surface and vision.
Scientists have successfully developed a stem cell-based treatment to restore vision in patients with severe corneal injuries using their own eye stem cells.
This technique, tested in a U.S. clinical trial called CALEC, involves harvesting limbal stem cells from a patient’s healthy eye, growing them in a lab, and transplanting them into the damaged eye.
Key Results:
- 93% success rate in restoring the corneal surface.
- 72% of patients showed significant vision improvement within 12–18 months.
- No major side effects or rejection risks were observed since the treatment uses the patient’s own cells.
Why It Matters:
This breakthrough offers hope to patients with limbal stem cell deficiency, often caused by burns, trauma, or infections, where standard corneal transplants fail. Unlike traditional grafts, this approach doesn’t require donor tissue or immunosuppressive drugs and helps regenerate the cornea naturally.
Final Thought:
This is a major step forward in regenerative eye medicine, proving that personalized stem cell therapy can safely and effectively restore both the eye’s surface and vision.
